Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02336737 · ClinicalTrials.gov registry record · NA
SentiMag® Intraoperative Comparison in Breast Cancer
A NA study of Breast Cancer, sponsored by Endomagnetics.
- Completed
- Registry status
- NA
- Development phase
- 160
- Enrollment target
- 6
- Study locations
NCT02336737: Completed NA study of Breast Cancer, sponsored by Endomagnetics.
NCT02336737 is a NA study of Breast Cancer that has completed, run by Endomagnetics. The registered enrollment target is 160 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (94% lower). The trial reports 6 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02336737, a NA study of Breast Cancer, has completed, sponsored by Endomagnetics.
- COMPLETED
- Registry status
- NA
- Development phase
- 160 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this pivotal study is to provide prospective evidence that the SentiMag®/SiennaXP® is safe and non-inferior to the current standard of care for lymph node localization in patients with breast cancer as part of a sentinel lymph node biopsy (SLNB) procedure and to summarize measures of product safety and performance.
Primary Outcome
The proportion of lymph nodes detected intraoperatively by SentiMag and SiennaXP in relation the proportion of lymph nodes detected by the combination of Technetium Sulfur Colloid and Isosulfan blue dye
Conditions Studied
Interventions
- DEVICE SiennaXP
- DRUG Technetium Tc99m Sulfur Colloid
- DRUG Isosulfan blue dye
Study Locations (6)
California
- University of California San Diego Moores Cancer Center - La Jolla
- University of California Davis Comprehensive Cancer Center - Sacramento
- UCSF Carol Franc Buck Breast Care Center - San Francisco
Texas
- Dallas Surgical Group - Dallas
- University of Texas MD Anderson Cancer Center - Houston
Pennsylvania
- Coordinated Health Breast Care Specialists - Allentown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2015-01 |
| Est. Completion | 2015-12 |
| Phase | NA |
What the finished NCT02336737 record still lists
NCT02336737 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which SiennaXP is the first listed.
NCT02336737 lists 6 locations in 3 states (California, Texas, Pennsylvania).
Frequently Asked Questions
What is clinical trial NCT02336737 about?
NCT02336737 is a clinical study titled "SentiMag® Intraoperative Comparison in Breast Cancer". The purpose of this pivotal study is to provide prospective evidence that the SentiMag®/SiennaXP® is safe and non-inferior to the current standard of care for lymph node localization in patients with breast cancer as part of a sentinel lymph node biopsy (SLNB) procedure and to summarize measures of ...
What is the current status of trial NCT02336737?
This trial is currently completed. It is a NA study. The enrollment target is 160 participants. The study started on 2015-01. Estimated completion is 2015-12.
What conditions does trial NCT02336737 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT02336737?
The interventions under investigation include: SiennaXP (DEVICE), Technetium Tc99m Sulfur Colloid (DRUG), Isosulfan blue dye (DRUG).
Who is sponsoring clinical trial NCT02336737?
This trial is sponsored by Endomagnetics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02336737 being conducted?
This trial has 6 study locations across California, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02336737's enrollment target sits among peer trials
160 433rd of 1224 higher than 790 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
-
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
RECRUITING · NA
-
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
RECRUITING · NA
-
A Randomized Controlled Trial (RCT) to Determine the Efficacy of a Multidisciplinary CBT Based Pain Management Program for the Treatment of Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) in Breast Cancer Survivors
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia